Mortality among patients with pulmonary non-tuberculous mycobacteria disease

International Journal of Tuberculosis and Lung Disease

Volumn 20, Issue 5, 2016, Pages 582-587

  Fleshner, M ^a,b   Olivier, K N ^c   Shaw, P A ^d,e   Adjemian, J ^a,b   Strollo, S ^a,b   Claypool, R J ^b   Folio, L ^f   Zelazny, A ^f   Holland, S M ^b   Prevots, D R ^a,b  

^a Department of Biostatistics   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d Division of Clinical Research   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZITHROMYCIN; C REACTIVE PROTEIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; ETHAMBUTOL; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; RIFABUTIN; RIFAMPICIN; TIGECYCLINE;

ADULT; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CAUCASIAN; COMORBIDITY; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; FIBROCAVITARY DISEASE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; PULMONARY NON TUBERCULOUS MYCOBACTERIA DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TERTIARY CARE CENTER; UNITED STATES; ATYPICAL MYCOBACTERIUM; CLASSIFICATION; DIAGNOSTIC IMAGING; EPIDEMIOLOGY; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; LUNG; LUNG FIBROSIS; MICROBIOLOGY; MIDDLE AGED; MORTALITY; NATIONAL HEALTH ORGANIZATION; PROPORTIONAL HAZARDS MODEL; RESPIRATORY TRACT INFECTION; TIME FACTOR; X-RAY COMPUTED TOMOGRAPHY;

FEMALE; HUMANS; HYPERTENSION, PULMONARY; KAPLAN-MEIER ESTIMATE; LUNG; MALE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; NATIONAL INSTITUTES OF HEALTH (U.S.); NONTUBERCULOUS MYCOBACTERIA; PROPORTIONAL HAZARDS MODELS; PULMONARY FIBROSIS; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 84963944152     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0807     Document Type: Article

References (33)

1. Adjemian J, Olivier K N, Seitz A E, Holland S M, Prevots D R. Prevalence of nontuberculous mycobacterial lung disease in US Medicare beneficiaries. Am J Respir Crit Care Med 2012; 185: 881-886.
2. Prevots D R, Shaw P A, Strickland D, et al. Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med 2010; 182: 970-976.
3. Cassidy P M, Hedberg K, Saulson A, McNelly E, Winthrop K L. Non-tuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis 2009; 49: e124-e129.
4. Ballarino G J, Olivier K N, Claypool R J, Holland S M, Prevots D R. Pulmonary nontuberculous mycobacterial infections: antibiotic treatment and associated costs. Respir Med 2009; 103: 1448-1455.
5. Field S K, Fisher D, Cowie R L. Mycobacterium avium complex pulmonary disease in patients without HIV infection Chest 2004; 126: 566-581.
6. The Research Committee of the British Thoracic Society. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment. Int J Tuberc Lung Dis 2002; 6: 628-634.
7. Griffith D E, Aksamit T, Brown-Elliott B A, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of non-tuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367-416.
8. Andrejak C, Thomsen V O, Johansen I S, et al. Non-tuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med 2010; 181: 514-521.
9. Hayashi M, Takayanagi N, Kanauchi T, Miyahara Y, Yanagisawa T, Sugita Y. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 2012; 185: 575-583.
10. Mirsaeidi M, Machado RF, Garcia JG, Schraufnagel DE.Non-tuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study. PLOS ONE 2014; 9: e91879.
11. Kim R D, Greenberg D E, Ehrmantraut M E, et al. Pulmonary non-tuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178: 1066-1074.
12. Chalmers J D, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014; 189: 576-585.
13. Ito Y, Hirai T, Maekawa K, et al. Predictors of 5-year mortality in pulmonary mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis 2012; 16: 408-414.
14. Kotilainen H, Valtonen V, Tukiainen P, Poussa T, Eskola J, Jarvinen A. Prognostic value of American Thoracic Society criteria for non-tuberculous mycobacterial disease: a retrospective analysis of 120 cases with four years of follow-up. Scand J Infect Dis 2013; 45: 194-202.
15. Morimoto K, Iwai K, Uchimura K, et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc 2014; 11: 1-8.
16. Okumura M, Iwai K, Ogata H, et al. Clinical factors on cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium complex disease. Intern Med 2008; 47: 1465-1472.
17. Gommans E P, Even P, Linssen C F, et al. Risk factors for mortality in patients with pulmonary infections with non-tuberculous mycobacteria: a retrospective cohort study. Respir Med 2015; 109: 137-145.
18. Hoefsloot W, van Ingen J, Andrejak C, et al. The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J 2013; 42: 1604-1613.
19. Miller T L, Wilson F A, Pang J W, et al. Mortality hazard and survival after tuberculosis treatment. Am J Public Health 2015; 105: 930-937.
20. Okumura M, Iwai K, Ogata H, et al. [Clinical studies on the pathogenetic factors of cavitary and nodular bronchiectatic types in pulmonary Mycobacterium avium complex disease]. Nihon Kokyuki Gakkai Zasshi 2006; 44: 3-11. [Japanese]
21. Harada S, Harada Y, Ochiai S, et al. [A clinical study of deceased cases of pulmonary M. avium complex (MAC) disease-: in contrast with survived cases followed-up for 5 years or longer]. Kekkaku 2002; 77: 709-716. [Japanese]
22. Shu C C, Lee C H, Hsu C L, et al. Clinical characteristics and prognosis of nontuberculous mycobacterial lung disease with different radiographic patterns. Lung 2011; 189: 467-474.
23. Yano Y, Kitada S, Mori M, et al. Pulmonary disease caused by rapidly growing mycobacteria: a retrospective study of 44 cases in Japan. Respiration 2013; 85: 305-311.
24. Carrillo M C, Patsios D, Wagnetz U, Jamieson F, Marras T K. Comparison of the spectrum of radiologic and clinical manifestations of pulmonary disease caused by Mycobacterium avium complex and Mycobacterium xenopi. Can Assoc Radiol J 2014; 65: 207-213.
25. Kang H K, Park H Y, Kim D, et al. Treatment outcomes of adjuvant resectional surgery for nontuberculous mycobacterial lung disease. BMC Infect Dis 2015; 15: 76.
26. Tung Y J, Bittaye S O, Tsai J R, et al. Risk factors for microbiologic failure among Taiwanese adults with Mycobacterium abscessus complex pulmonary disease. J Microbiol Immunol Infect 2015; 48: 437-445.
27. Sohn H, Kim H J, Kim J M, Jung K O, Koh W J, Shin S J. High virulent clinical isolates of Mycobacterium abscessus from patients with the upper lobe fibrocavitary form of pulmonary disease. Microb Pathog 2009; 47: 321-328.
28. Koh W J, Kim Y H, Kwon O J, et al. Surgical treatment of pulmonary diseases due to non-tuberculous mycobacteria. J Korean Med Sci 2008; 23: 397-401.
29. Watanabe M, Hasegawa N, Ishizaka A, et al. Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. Ann Thorac Surg 2006; 81: 2026-2030.
30. de Mello K G, Mello F C, Borga L, et al. Clinical and therapeutic features of pulmonary nontuberculous mycobacterial disease, Brazil, 1993-2011. Emerg Infect Dis 2013; 19: 393-399.
31. Kotilainen H, Valtonen V, Tukiainen P, Poussa T, Eskola J, Jarvinen A. Clinical symptoms and survival in non-smoking and smoking HIV-negative patients with non-tuberculous mycobacterial isolation. Scand J Infect Dis 2011; 43: 188-196.
32. Kuroda F, Tanabe N, Igari H, et al. Non-tuberculous mycobacterium diseases and chronic thromboembolic pulmonary hypertension. Intern Med 2014; 53: 2273-2279.
33. Park I K, Hsu A P, Tettelin H, et al. Clonal diversification, changes in lipid traits and colony morphology in Mycobacterium abscessus clinical isolates. J Clin Microbiol 2015; 53: 3438-3447.